PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33771885-8	2021	Implications: We identified common and reproducible genomic alterations in CTCs from AR-V7 negative mCRPC men associated with poor outcomes during enzalutamide/abiraterone treatment, including CNAs in genes linked to lineage plasticity and epigenetic signaling, DNA repair, AR, TP53/RB1, PTEN, and WNT pathways.	enzalutamide	147-159	RB transcriptional corepressor 1	Homo sapiens	283-286	
34728570-6	2022	Enzalutamide induced the expression of DNMT3A and DNMT3B in prostate cancer cells with a potential role of p53 and pRB in this process.	enzalutamide	0-12	RB transcriptional corepressor 1	Homo sapiens	115-118	
31587305-3	2020	Other studies have shown that knockdown of RB1 and TP53 increases the expression of neuroendocrine markers, decreases the sensitivity to enzalutamide, and increases the expression of SOX2.	enzalutamide	137-149	RB transcriptional corepressor 1	Homo sapiens	43-46